Skip to main content
PharmaEssentia Corporation logo

PharmaEssentia Corporation — Investor Relations & Filings

Ticker · 6446 ISIN · TW0006446008 LEI · 54930001GNQLDIFASK68 TW Manufacturing
Open in API
Filings indexed 36 across all filing types
Latest filing 2026-04-09 Director's Dealing
Country TW Taiwan
Listing TW 6446

About PharmaEssentia Corporation

http://www.PharmaEssentia.com

PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.

Recent filings

Filing Released Lang Actions
115年03月內部人持股異動(事後)
Director's Dealing Classification · 92% confidence The document is a detailed table disclosing shareholdings and monthly changes (increases/decreases) for directors, executives, and their related parties, consistent with insider share transaction reporting. It is not a general corporate report, but a regulatory disclosure of director/executive personal shareholdings and movements. Therefore, it falls under Director's Dealing (insider transactions).
2026-04-09 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 75% confidence The document is a regulatory disclosure detailing shareholdings and pledged shares of the company’s directors, independent directors, and senior officers. It is not an earnings release, proxy statement, or annual report. Instead it matches the “Director’s Dealing” category, which covers insider share transaction and holding disclosures by directors and executives.
2026-04-09 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 85% confidence The document is extremely short (25 characters) and contains a generic notice from a public information system (“公開資訊觀測站”) stating no data is found. It does not convey any substantive financial report, announcement of a meeting, or regulatory filing in a specific category. As a result, it falls under the fallback category of Regulatory Filings (RNS).
2026-04-05 Chinese
115年3月營業收入
Regulatory Filings Classification · 75% confidence The document is a monthly revenue summary table provided on Taiwan’s Market Observation Post System (MOPS) by a listed company. It is a regulatory-required disclosure of operating revenues, not an AGM presentation, earnings release, annual or interim report, nor any financing, governance or legal notice. It is a generic regulatory announcement (miscellaneous filing) of monthly/cumulative revenue figures. Therefore, it falls under the fallback category for regulatory filings.
2026-04-05 Chinese
本公司P1101用於早前期原發性骨髓纖維化或低或中度 風險1級的明顯原發性骨髓纖維化之第三期臨床試驗獲數據 安全監督委員會（DSMB）正面回應，建議持續收案
Regulatory Filings Classification · 85% confidence The document is an official disclosure filed on Taiwan’s Public Information Observation Station (公開資訊觀測站) under Clause 10 for “important events,” providing a clinical‐trial progress update for the company’s new drug. It is neither a financial report (10-K, IR), earnings release, nor an investor presentation, but a routine regulatory announcement of operational news. Therefore it falls under the fallback category for miscellaneous regulatory disclosures.
2026-03-30 Chinese
115年03月內部人持股轉讓(事前)
Director's Dealing Classification · 95% confidence The document lists an insider share transaction (a director ‘董 事 本 人’ named 詹青柳) transferring shares (贈與) of company code 6446 (藥華藥) on a specific date, with details on pre- and post-transfer holdings. This fits the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives.
2026-03-30 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.